within Pharmacolibrary.Drugs.ATC.L;

model L01CA04
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 7.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0166,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Vinorelbine is a semi-synthetic vinca alkaloid antineoplastic agent that inhibits mitosis by binding to tubulin. It is primarily used in the treatment of non-small cell lung cancer and advanced breast cancer. Vinorelbine is approved and used in clinical oncology practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult cancer patients, after intravenous administration, based on population PK modeling.</p><h4>References</h4><ol><li><p>Levêque, D, &amp; Jehl, F (1996). Clinical pharmacokinetics of vinorelbine. <i>Clinical pharmacokinetics</i> 31(3) 184–197. DOI:<a href=\"https://doi.org/10.2165/00003088-199631030-00003\">10.2165/00003088-199631030-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8877249/\">https://pubmed.ncbi.nlm.nih.gov/8877249</a></p></li><li><p>Yang, Y, et al., &amp; Zhang, L (2019). A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. <i>Journal of thoracic disease</i> 11(8) 3347–3359. DOI:<a href=\"https://doi.org/10.21037/jtd.2019.08.22\">10.21037/jtd.2019.08.22</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31559038/\">https://pubmed.ncbi.nlm.nih.gov/31559038</a></p></li><li><p>Pétain, A, et al., &amp; Ferré, P (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. <i>Cancer chemotherapy and pharmacology</i> 84(2) 373–382. DOI:<a href=\"https://doi.org/10.1007/s00280-019-03872-9\">10.1007/s00280-019-03872-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31134323/\">https://pubmed.ncbi.nlm.nih.gov/31134323</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CA04;
